Lapatinib ditosylate
- CAS NO.:388082-78-8
- Empirical Formula: C41H40ClFN4O11S3
- Molecular Weight: 925.46
- MDL number: MFCD09264195
- EINECS: 642-915-3
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-11-19 15:53:33
What is Lapatinib ditosylate?
The Uses of Lapatinib ditosylate
Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.
The Uses of Lapatinib ditosylate
anticancer
The Uses of Lapatinib ditosylate
binds to a(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors atypical antipsychotic agent
What are the applications of Application
Lapatinib ditosylate is a selective and effective inhibitor of ErbB-2 and EGFR dual tyrosine kinases
Definition
ChEBI: Lapatinib ditosylate monohydrate is a member of quinazolines.
General Description
Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of <0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2=300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.
Properties of Lapatinib ditosylate
Melting point: | >200oC (dec.) |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
solubility | DMSO (Slightly), Methanol (Slightly) |
form | Solid |
color | Yellow |
CAS DataBase Reference | 388082-78-8(CAS DataBase Reference) |
Safety information for Lapatinib ditosylate
Computed Descriptors for Lapatinib ditosylate
Abamectin manufacturer
Neugen Labs
Salvavidas Pharmaceutical Pvt., Ltd.
Humble Healthcare Limited
Sumar Biotech LLP
Aspen Biopharma Labs Pvt Ltd
New Products
4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
388082-78-8 Lapatinib Ditosylate monohydrate 98%View Details
388082-78-8 -
388082-78-8 98%View Details
388082-78-8 -
Lapatinib Ditosylate monohydrate 99%View Details
388082-78-8 -
Lapatinib Ditosylate monohydrate 388082-78-8 98%View Details
388082-78-8 -
388082-78-8 98%View Details
388082-78-8 -
Lapatinib ditosylate monohydrate 98.00% CAS 388082-78-8View Details
388082-78-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Lithium ClavulanateView Details
61177-44-4